Search
-
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
Media
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study
https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/
First published: 23 September 2015
-
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
Media
GSK announced that its losmapimod phase III study, review of data from part A,3,503 patients did not indicate efficacy against larger part B
https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-latitude-timi-60-losmapimod-cardiovascular-study/
First published: 27 October 2015
-
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
Media
GSK today announced it has received positive top-line results from the phase III programme investigating sirukumab
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-top-line-results-from-sirukumab-phase-iii-programme-supporting-regulatory-filings-for-rheumatoid-arthritis-in-2016/
First published: 16 December 2015
-
GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets
Media
Two transactions further strengthen HIV pipeline and outlook
https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/
First published: 18 December 2015
-
GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency
Media
GSK added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system.
https://www.gsk.com/en-gb/media/press-releases/gsk-adds-detailed-clinical-trial-data-to-multi-sponsor-request-system-as-part-of-continued-commitment-to-data-transparency/
First published: 02 January 2014
-
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
Media
GSK announced headline results from its second phase III study with darapladib evaluating efficacy in adults with acute coronary syndrome.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-with-darapladib-did-not-meet-primary-endpoint-in-patients-following-an-acute-coronary-syndrome/
First published: 13 May 2014
-
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD
Media
GSK announced that EMA's CHMP is recommending marketing authorisation for umeclidinium, treatment to relieve symptoms in patients with COPD.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-incruse-umeclidinium-for-the-treatment-of-copd/
First published: 20 February 2014
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
Media
GSK announced its decision to stop the Phase III trial of MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients.
https://www.gsk.com/en-gb/media/press-releases/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer/
First published: 02 April 2014
-
GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors
Media
GSK announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-sir-philip-hampton-to-the-board-of-directors/
First published: 25 September 2014
-
GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) (1)
Media
GSK announced submission to EMA for eltrombopag (Revolade™) for the treatment of patients with SAA who have insufficient response to IST.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade-1/
First published: 12 November 2014